Mahendra Patil, MD
Child & Adolescent Psychiatry · Philadelphia, PANPI 1558424945
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 361 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Among child & adolescent psychiatry clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 361 payments — averaging $18.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$920
- Alkermes, Inc.$860
- Lundbeck LLC$783
- Sunovion Pharmaceuticals Inc.$576
- Neurocrine Biosciences, Inc.$380
- plus $2K from 14 others
What the payments were for
- Food & beverage$6,51098%
- Education$1292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 65 | $1,100 |
| Otsuka America Pharmaceutical, Inc. | 51 | $920 |
| Alkermes, Inc. | 35 | $860 |
| Lundbeck LLC | 38 | $783 |
| Sunovion Pharmaceuticals Inc. | 42 | $576 |
| Neurocrine Biosciences, Inc. | 20 | $380 |
| Teva Pharmaceuticals USA, Inc. | 15 | $369 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $258 |
| Neos Therapeutics, LP | 15 | $249 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $248 |
| Axsome Therapeutics, Inc. | 12 | $232 |
| Corium, LLC | 10 | $150 |
| Supernus Pharmaceuticals, Inc. | 6 | $140 |
| Ironshore Pharmaceuticals Inc. | 5 | $95 |
| Vertical Pharmaceuticals, LLC | 4 | $59 |
| Tris Pharma Inc | 4 | $58 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Johnson & Johnson | 2 | $45 |
| Acadia Pharmaceuticals Inc | 2 | $44 |
| Neuronetics, Inc. | 2 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$472
- ARISTADA INITIO$118
How this compares
$6,639 in reported general payments places this provider in the 90th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.
See all child & adolescent psychiatry providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 42 | $393,927 |
| VraylarCariprazine Hcl | 132 | $190,436 |
| RexultiBrexpiprazole | 94 | $143,837 |
| CaplytaLumateperone Tosylate | 29 | $57,106 |
| LybalviOlanzapine/Samidorphan Malate | 31 | $55,178 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 237 | $40,836 |
| AristadaAripiprazole Lauroxil | 11 | $33,436 |
| Abilify MaintenaAripiprazole | 12 | $28,493 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 32 | $22,209 |
| TrintellixVortioxetine Hydrobromide | 32 | $16,352 |
| QelbreeViloxazine Hcl | 16 | $15,945 |
| VyvanseLisdexamfetamine Dimesylate | 21 | $12,627 |
| Adderall XrDextroamphetamine/Amphetamine | 33 | $9,004 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 109 | $7,864 |
| Lurasidone Hcl | 60 | $6,858 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $369 | $393,92742 claims |
| AbbVieVraylar | $1,100 | $190,436132 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $920 | $172,330106 claims |
| Alkermes, Inc.Lybalvi, Aristada | $860 | $88,61442 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $248 | $57,10629 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse, Adderall | $258 | $35,23274 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $140 | $15,94516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 200 child & adolescent psychiatry providers in Pennsylvania.
Other child & adolescent psychiatry in Philadelphia
- Thomas WindPhiladelphia$17K
- Laura AdangPhiladelphia$15K
- Christoph LamPhiladelphia$13K
- David LopezPhiladelphia$3K
- Pamela RalphPhiladelphia$3K
- Fathima MusthaqPhiladelphia$2K
- Michael InestaPhiladelphia$1K
- Stacy McAllisterPhiladelphia$1K
- Alejandra WortmanPhiladelphia$812
- Dennis BorczonErie$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.